Patent · US Active

Targeting of interleukin-1 and -18 signaling in treatment of septic shock

US9919048B2 · kind B2 · utility

0Cited by

2References

17Claims

0Family size

Assignees

VIB VZW · BE
UNIVERSITEIT GENT · BE

Inventors

Peter Vandenabeele · Sint-Amandsberg, BE
Anje CAUWELS · Merelbeke, BE
Tom Vandenberghe · Haasdonk, BE

Key dates

Filing date	Jan 15, 2015
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Jan 15, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.